Framingham risk score ( 6, 23 ) , and allow reclassifi cation of a signifi cant number of subjects in intermediate Framingham risk category into higher or lower risk categories ( 24 ) . Thus, OxPL/apoB appears to refl ect the adverse consequences of highly atherogenic Lp(a) particles on CVD outcomes, but is also independently associated with CVD risk above and beyond Lp(a) levels in certain populations ( 6, 14 ) .
More recently, we also demonstrated that PLG of a variety of species contains covalently bound OxPLs ( 25 ) . In contrast to the pro-atherogenic effects of OxPLs on Lp(a), OxPLs on PLG promote fi brinolysis, whereas the absence of OxPLs on PLG result in delayed fi brinolysis, which would be predicted to be atheroprotective ( 25 ) .
In this study, we evaluate the potential determinants of OxPL binding on apo(a)/Lp(a) using several techniques, including isolated Lp(a) from humans, plasma from apes and monkeys, and recombinant apo(a) [r-apo(a)] constructs with a variety modifi cations encompassing apo(a) differences in various species. We also examine unique transgenic murine models expressing human Lp(a), including an apo(a) with mutations in a canonical lysine binding site (LBS) on KIV 10 , which is based on the sequences derived from KIV of PLG ( 26 ) .
evidence that Lp(a) is a genetic risk factor that may causally mediate CVD ( 9, 10 ) . However, the underlying mechanisms by which Lp(a) mediates atherogenicity are not well understood ( 11 ) .
We made the observation that Lp(a) is a preferential lipoprotein carrier of oxidized phospholipids (OxPLs) using a variety of experimental and clinical approaches (12) (13) (14) (15) (16) . Furthermore, we developed an ELISA that quantitates phosphocholine (PC)-containing OxPLs on human apoB lipoproteins (OxPL/apoB), which primarily refl ects the presence of OxPLs on the most atherogenic Lp(a) particles ( 17 ) . OxPLs are highly prevalent in human vulnerable plaques ( 18 ) and in total chronic coronary occlusions ( 19 ) . We have demonstrated that plasma OxPL/apoB levels identify angiographically-determined coronary artery disease (CAD) ( 14 ) , predict the presence and progression of carotid and femoral atherosclerosis ( 20 ) and development of symptomatic peripheral arterial disease ( 21 ) , and are elevated following acute coronary syndromes ( 12 ) and following percutaneous coronary intervention ( 22 ) . Importantly, increased baseline levels of OxPL/apoB predict 15 year occurrence of new CVD events in previously healthy subjects independent of traditional risk factors and their Genetic architecture of PLG and apo(a). The illustration depicts chromosome 6q26 containing the genes for PLG and apo(a) (LPA), which is transcribed into apo(a) containing KIV 1 , various repeats of KIV 2 , KIV 3 to KIV 8 , KIV 9 that contains an additional cysteine which covalently binds to apoB-100 of Lp(a) via a disulfi de bond (S), KIV 10 that contains the LBS, and the inactive protease domain .
by guest, on www.jlr.org Downloaded from apo(a) cDNA. The 8.6 kb LBS mutant apo(a) expression vector (containing the Apoe promoter, Apoe intron 1, the LBS mutant apo(a) cDNA, and LE6) was excised from pRK5 ha8Lysmuta with Sac II, purifi ed, and microinjected into C57BL/6×SJL zygotes. The resultant mice were designated LBS ؊ apo(a) mice.
Breeding of 8K-IV WT and LBS ؊ r-apo(a)/Lp(a) mice
Hemizygous LBS ؊ apo(a) mice were crossed with hemizygous mice expressing human apoB-100 only, which were previously generated with an apoB mutation in codon 2,153 that prevented apoB-48 synthesis ( 36 ) . All mice were on a C57/SJL background, weaned at 28 days of age, housed in a barrier facility with a 12 h light/12 h dark cycle, and fed a chow diet containing 4.5% fat (Ralston Purina, St. Louis, MO). Mice were genotyped by obtaining DNA from the tip of the tail and performing PCR using MyTaq HS Red Mix (BIOLINE, Inc., Taunton, MA). Forward and reverse primers for apo(a) were 5 ′ -GACGGGAGACAGAGTGAAGC-3 ′ and 5 ′ -TACCTAAACCACGCCAGGAC-3 ′ , respectively, and for apoB 5 ′ -GAAGAACTTCCGGAGAGTTGCAAT-3 ′ and 5 ′ -CTCTTAGC CCC-ATTCAGCTCTGAC-3 ′ , respectively. DNA samples were placed in a 1.5% agarose subgel containing ethidium bromide, run at 100 V for about 45 min, and visualized in a fl uorescence reading chamber.
Expression of 8K-IV WT apo(a) and 8K-IV LBS ؊ r-apo(a) constructs in mammalian cells
Recombinant WT 8K-IV apo(a) was expressed in human embryonic 293 kidney cells (HEK293) and purifi ed with a lysine Sepharose column as previously described ( 32 ) . The original 8K construct in the pRK5 ha vector contained no selection gene. To introduce the 8K-IV LBS ؊ r-apo(a) cDNA into HEK293 cells, a cotransfection assay was performed using pcDNA3 containing a G418 Lipofectamine transfection reagent (Invitrogen, Carlsbad, CA) using a 3:1 ratio in order to ensure that the gene of interest was expressed. After several rounds of selection, individual colonies were selected and grown. Each colony was tested for expression by concentrating the media with 10,000 NMWL Amicon Ultra Centrifugal Filter Units from Millipore (Billerica, MA), purifying the 8K-IV LBS ؊ r -apo(a) by size exclusion chromatography (SW400 resin), and analyzing by both ELISA and Western blot. Nontransfected cells were also analyzed as a negative control.
Antibodies
Monoclonal antibodies MB47 specifi c for human apo B-100, LPA4 specifi c for apo(a), and E06 specifi c for the PC headgroup of OxPLs were previously described in detail ( 22 ) .
Tandem LC-MS/MS analysis of OxPLs on r-apo(a) constructs
LC-MS/MS was utilized to assess the covalent binding of PCcontaining OxPLs on the WT 17K r-apo(a) as well as the r-apo(a) 17K ⌬ Asp 57 , which has a substitution of Asp 57 to Ala 57 in the LBS of KIV 10 . The 17K and 17K ⌬ Asp 57 r-apo(a) were thermally denatured, the disulfi de bonds reduced by dithiothreitol (DTT), alkylated by iodoacetamide, and then digested with trypsin. In brief, to 100 l of r-apo(a) (1 g/ l in deionized water) was added 100 l of ammonium bicarbonate buffer (50 mM pH 8) and 2 l of 1 M DTT. The mixture was incubated at 50°C for 15 min. Twenty-fi ve microliters of a saturated solution of iodoacetamide in DI water was added to the reaction mixture, which was kept in the dark at room temperature for 15 min. One half of the reaction mixture was then hydrolyzed in 30% NH 4 OH for 14 h and the reaction mixture subjected to vacuum overnight to remove NH 4 OH. The residue was reconstituted in 100 l ammonium bicarbonate buffer and digested in trypsin with a molar ratio of 50:1 (r-apo(a):trypsin) overnight. The digested peptides were purifi ed by solid phase Figure 2A displays the composition of apo(a) in various species used in this study. Compared with humans, all species except baboons and orangutans have differences in the seven amino acid LBS of KIV 10 . The r-apo(a) constructs studied contain a variety of modifi cations of Ks and KIV 10 LBS, including the Asp 57 → Ala 57 variant found in the chimpanzee and gorilla. Figure 2B displays the r-apo(a) variants representing naturallyoccurring isoforms as well as various deletion and point mutants. These r-apo(a) constructs, which were derived from the original published human cDNA of apo(a), were generated from the expression plasmid pRK5 ha17 and their construction, expression, and purifi cation have been previously described (27) (28) (29) (30) ) were mutated to alanine with similar techniques as for the above r-apo(a) constructs. A construct comprised of the 8K-IV wild-type (WT) and 8K-IV lysine-binding defective mutant (LBS ؊ ) r-apo(a), used to generate transgenic mice with a truncated apo(a) as previously described (31) (32) (33) , was also studied and their construction is described below.
METHODS

Composition of apo(a) of various species and of r-apo(a) constructs
Human subjects
All samples were acquired according to a study protocol approved by the University of California, San Diego Human Subjects Protection program and all study subjects gave their written informed consent before entering the study.
Source of animal plasma samples
Plasma samples from bonobos ( Pan paniscus ) (n = 4), chimpanzees ( Pan troglodytes ) (n = 7), gorillas ( Gorilla gorilla ) (n = 6), and baboons ( Papio species ) (n = 3) were provided by the San Diego Wild Animal Park, and plasmas from cynomolgus monkeys ( Macaca fascicularis ) (n = 4) were obtained as previously described ( 34 ) . WT C57BL/6×SJL, Apoe Ϫ / Ϫ , and Ldlr Ϫ / Ϫ mice were derived from existing mouse colonies. Apo(a) and Lp(a) transgenic mice with an apo(a) construct containing the apoE promoter and 8 KIV units (KIV 1 , a single copy of KIV 2 , a fusion of KIV 3 and KIV 5 , and KIV 6 to KIV 10 ), KV, and the inactive protease-like domain on a C57BL/6×SJL background (n = 15) were previously described [termed 8K-IV apo(a)/Lp(a) mice] ( 33 ). These mice express both human apo(a) and human apoB-100 and have both elevated apo(a) and Lp(a) levels and increased levels of OxPLs on their apo(a)/Lp(a) particles (31) (32) (33) . All animal studies were conducted using protocols approved by the University of Califormia, San Diego Institutional Animal Care and Use Committee.
Generation of 8K-IV apo(a)/Lp(a) mice with defective KIV 10 LBS
To generate 8K-IV apo(a)/Lp(a) mice with defective KIV 10 LBS [8K-IV LBS Ϫ apo(a)/Lp(a) mice], the Asp 55 and Asp 57 residues in the KIV 10 LBS apo(a) cDNA construct were replaced by Ala 55 and Ala 57 residues, as previously described ( 35 ) . The vector, pRK5 ha8Lysmuta, was digested with Bgl II, polished with Pfu DNA polymerase (Stratagene, La Jolla, CA), and cut with Eco RI. The LBS mutant apo(a) fragment was inserted into a liver cDNA expression vector that had been digested with Kpn I and polished and cut as described above. Eco RI sites were introduced into the 5 ′ and 3 ′ ends of the Apoe hepatic control region (LE6) by PCR with primers 5 ′ -CGGGAATTCTGCAGGCTCAGAG-3 ′ and 5 ′ -GGGAATTCGAG-C T CCGCGGCAGCCTGACCA-3 ′ (the 3 ′ primer contained a nested Sac II site). The LE6 was then ligated to the 3 ′ end of the LBS mutant by guest, on www.jlr.org Downloaded from Fig. 2 . Description of the species differences in apo(a) at the various apo(a) Ks (A) and the various r-apo(a) peptides (B) used in this study. The domain structure of the full-length r-apo(a) construct comprising 17 kringles (17K) is presented at the top, where squares resemble individual Ks, subscripts 1 to 10 denote the subtypes of KIV sequences, KV denotes the KV-like sequence and P is the inactive protease domain. The T-bar over KIV 9 indicates the location of the free-cysteine by which apo(a) is covalently bound to apoB-100 in Lp(a) via a disulfi de bond. The dot within KIV 10 (PEIPC) , which are highly bioactive OxPLs ( 41, 42 ) . To identify specifi c species of OxPLs in the lipid phase of Lp(a) (i.e., extractable OxPLs), we employed reversed phase liquid chromatography directly coupled to a triple quadrupole MS (LC-MS/MS), as recently described ( 40, 43, 44 , and (PC-OxPL + H) + are formed when operating the ion source in positive electrospray mode. The MS is operated in PIS mode using a collision energy setting of 35 V and a mass scan range of 500 to 900 atomic mass units. In a specifi ed PIS mode, the MS detects all precursor ions within the mass scan range that produce the specifi ed fragment. PC and lyso-PC species produce the PC headgroup with m/z = 184, regardless of their parent mass or moiety. Applied Biosystems MS software (Analyst 1.5.1) using the extracted ion current (XIC) option allows a search for specifi ed precursor masses detected during the run.
Immunoblot analyses
Nonreducing SDS-PAGE of various apo(a) constructs, purifi ed Lp(a), and PLG (all at 1 g/ml) was carried out using precast gradient gels with 4-12% polyacrylamide concentrations and performed on a Xcell SureLock Mini-Cell system (Invitrogen) for 1.5 h in 1× MOPS SDS (NuPAGE MES SDS Running Buffer). The membranes were blocked with 5% nonfat dry milk in Tris-buffered saline and Tween for 1 h. Incubation with biotinylated LPA4 and biotinylated EO6 was performed on separate membranes in 1% nonfat dry milk in Tris-buffered saline and Tween overnight at 4°C. Protein detection was performed with streptavidin conjugated to horseradish peroxidase (HRP) from R and D Systems (Minneapolis, MN). For visualization Supersignal West Dura Extended Duration Substrate (Thermo Fisher Scientifi c Inc., Rockford, IL) was used as substrate and fl uorescence detected at 428 nm wavelength on a BioSpectrumAC imaging system using VisionWorksLS imaging acquisition and analysis software from UVP (Upland, CA). In these immunoblots, OxPLs are denoted to refl ect only E06-detectable OxPLs and not all OxPLs.
Statistics
For grouped numerical values, a mean value ± standard deviation (mean ± SD) was calculated. Analysis of quantitative parameters between groups was performed by two-tailed Student's unpaired ttest and within the same group by paired t -test or with repeatedmeasures one-way ANOVA. P р 0.05 was considered signifi cant. Data presented in the text and tables are mean ± SD and in fi gures mean value ± standard error of the mean (mean ± SEM).
RESULTS
The LBS of KIV 10 apo(a) consists of seven amino acids as follows by convention using the nomenclature of KV of PLG: Arg 35 . Because of the presence of several naming systems in the literature and differences in the number of amino acids in Ks between species, we provide a comparative summary of PLG KIV and KV, and apo(a) KIV 10 of various species in Fig. 3 . extraction. A Waters SepPak Vac C18 1 cc cartridge was preconditioned with 1 ml of CH 3 CN and 1 ml water; the digested peptides were loaded on the cartridge and washed with 1 ml of DI water. The peptides were eluted with 1 ml CH 3 CN. The solvent was evaporated and the residue reconstituted in 100 l of DI water.
LC-MS/MS analysis was carried out on a triple quadrupole instrument Thermal TSQ Vantage mass spectrometer coupled with a Waters NanoAcquity autosampler/UPLC system, as previously described ( 25, 37 ) . The LC separation was achieved on a trapping column with 5 cm of 5 m Jupiter C18 reverse phase material pressure-packed into a fused silica capillary (360 m o.d. × 100 m i.d.) and a resolving (analytical) column with 18 cm of 3 m Jupiter C18 material pressure-packed into a capillary (360 m o.d. × 100 m i.d .) with a laser-pulled tip for nano-electrospray ionization. Full scan monitoring was carried out to scan a mass range of m/z 350 to 1,500. Precursor ion scanning (PIS) monitoring was carried out to identify a product ion of m/z 184, which is characteristic for the PC headgroup.
Identifi cation of OxPLs in r-apo(a) constructs and plasma of humans and animals by chemiluminescent ELISA
The presence of apo(a), Lp(a), apoB, OxPL/apo(a), and OxPL/apoB in the various purifi ed recombinant proteins and mouse, animal, and human plasma was performed by a variety of immunoassays, as previously described ( 17, 31, 32 ) . Values are reported as relative light units (RLU) per 100 ms using chemiluminescent ELISA. Both direct plating of material and double antibody sandwich assays were utilized. Briefl y, for direct plating assays, r-apo(a) constructs (5 g/ml) or plasma (1:100 dilution) were plated on microtiter well plates overnight and apo(a) detected with antibody LPA4, OxPLs with antibody E06, and human apoB detected with antibody MB47, which does not cross-react with mouse apoB. For OxPL/apo(a) sandwich ELISA, LPA4 (5 g/ml) as capture antibody was plated overnight and constructs (5 g/ml) or plasma (1:100 to 1:400 dilution) added and OxPLs detected with biotinylated E06 (2 g/ml). The human, ape, and monkey plasma samples were usually used at a 1:400 dilution, which was established as the concentration at which the relationship is linear. For OxPL/apoB sandwich ELISA, MB47 (5 g/ml) as capture antibody was plated overnight and constructs (5 g/ml) or plasma (1:100 dilution) added and OxPLs detected with biotinylated E06 (2 g/ml). To determine Lp(a) levels in transgenic 8K-IV Lp(a) and 8K-IV LBS Ϫ Lp(a) mice, MB47 was immobilized on microtiter well plates for capture of human apoB, plasma added (1:400), and Lp(a) detected with antibody LPA4. To determine apo(a) levels in 8K-IV WT and 8K-IV LBS Ϫ r-apo(a) constructs, apo(a) was captured on microtiter well plates with LPA4 (5 g/ml), constructs (5 g/ml), and apo(a) detected with antibody LPA4 (the TRNYCRNPDAEIRP epitope for LPA4 is present on KIV-5, KIV-7, and KIV-8).
Identifi cation of OxPLs in human Lp(a) by LC-MS/MS
Lp(a) from subjects with hypercholesterolemia was isolated using density gradient ultracentrifugation followed by size exclusion chromatography with a Sephacryl S-400 or lysine Sepharose chromatography ( 16 ) . We extracted the OxPLs from intact purifi ed Lp(a) with 2:1 chloroform:methanol and analyzed the extract for the presence of 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphocholine (POVPC) ( 38-40 ), 1-palmitoyl-2-glutaroyl-sn -glycero-3 -phosphocholine (PGPC), and epoxy-isoprostane-phosphocholine 17K ⌬ Lys 42 , 17K ⌬ Lys 12/42 ), as well as fragments of the 17K construct including KIV 6 -P, KIV 7 -P, KIV 8 -P, KIV 9 -P, KIV 10 -P, KIV 6 -P, KIV 1-4 , KIV [5] [6] [7] [8] , KIV [5] [6] [7] [8] [9] , and KIV [5] [6] [7] [8] [9] [10] , and longer (23K, 27K, 30K, 33K) and shorter versions (6K, 12K, 14K) with variations of the KIV 2 repeats. 8K-IV indicates a short r-apo(a) version with a fusion of KIV 3 to KIV 5 that is identical to human apo(a) (WT) or has a disrupted LBS (LBS Ϫ ).
by guest, on www.jlr.org Downloaded from fairly similar ( Fig. 7A ) ( Fig. 7B ) . OxPLs were clearly present in apo(a) captured from the 17K and 17K ⌬ VP constructs, which are missing KV and KV and the protease domain respectively, the I4399M r-apo(a) construct, which represents the LPA single nucleotide polymorphism (SNP) rs3798220 with an isoleucine to methionine substitution associated with CAD ( 45, 46 ) and high OxPL/apoB levels ( 47 ), and human plasma. No OxPLs were detectable on 17K ⌬ Asp 57 r-apo(a) (chimpanzee and gorilla variant) that contains KV but has a substitution of alanine to aspartate 57 on KIV 10 .
Of note, Lys 12 and Lys 42 of KV had previously been postulated to bind OxPLs in both native apo(a) and r-apo(a) ( 13 ) ) on KV contained measurable levels of OxPLs, though the amounts bound were lower than other constructs. Indeed, constructs lacking KV altogether (17K ⌬ V and 17K ⌬ VP) had similar E06 reactivity as 17K.
Because the amounts of apo(a) captured on the plates were not identical for all constructs, we also determined the OxPL/apo(a) ratio ( Fig. 7C ) by dividing the OxPL content on the plate by apo(a) content on separate plates (i.e., data in Fig. 6B divided by data in Fig. 6A ), which shows similar results to the raw data.
Determination of the presence of OxPLs on r-apo(a) constructs using immunoblotting
Immunoblotting of various r-apo(a) constructs on SDS-PAGE identifi ed the key determinant of OxPL binding to be KIV 10 . OxPLs were present on Lp(a) and PLG, as expected, and on the r-apo(a) constructs 6K, 12K, 14K, 17K, 23K, 27K, 30K and 33K, 17K ⌬ V, 17K ⌬ VP, 17K ⌬ Lys 12/42 as well as truncated variants from KIV 6 -P (KIV 6 through protease domain) to KIV 10 -P. E06 immunoreactivity was not present on r-apo(a) consisting only of KIV [1] [2] [3] [4] , (KIV 2 ) 5 , or 17K ⌬ Asp 57 , or on r-apo(a) constructs lacking KIV 10 ( Fig. 8 ) . The presence of apo(a) in these constructs was confi rmed in parallel gels.
Determination of OxPLs on 17K WT and 17K ⌬ Asp 57 r-apo(a) constructs using LC-MS/MS
We next utilized LC-MS/MS to identify PC containing OxPLs on r-apo(a) constructs 17K and 17K ⌬ Asp 57 . The presence of PC on OxPLs of trypsin digests of r-apo(a)s was assessed by PIS for m/z = 184, which is the signature of PC. A number of prominent peptide peaks containing PC were present in the LC-chromatogram in the 17K construct ( Fig. 9A ) , indicating variously sized PC-modifi ed peptides. Interestingly, the 17K ⌬ Asp 57 r-apo(a), despite having no E06 immunoreactivity, had a similar but not
Determination of OxPLs on Lp(a) and apoB from humans, apes, and monkeys using ELISA techniques
OxPL/apoB and OxPL/apo(a) were measured in fi ve humans with widely different Lp(a) levels (data from >15,000 analyses of human plasma for OxPL/apoB and Lp(a) have been published previously ( 17 ) , therefore we only show data from fi ve representative humans for comparison), chimpanzees, bonobos, gorillas, baboons, and cynomolgus monkeys, and presented as mean levels and individual data points. Figure 4A , C demonstrates the levels of apoB and Lp(a) captured on the plates from each of the different samples. Figure 4B , D demonstrates the levels of OxPLs on apoB-100 particles and on apo(a) for each of these samples. It can be appreciated that OxPL/apoB and OxPL/apo(a) are mainly present in the humans with high Lp(a) levels, as previously well documented ( 17 ) . However, all other species had essentially undetectable OxPL/apoB and OxPL/apo(a) levels, with values at or below the sensitivity of these assays ( Fig. 4B, D ) . Importantly, E06 immunoreactivity was not present in chimpanzees and gorillas whose Lp(a) is known to contain KV.
Determination of OxPLs on 8K-IV WT apo(a) and 8K-IV LBS
؊ apo(a) recombinant constructs
Immunoblot analysis of supernatants of HEK293 cells expressing 8K-IV WT r-apo(a) and 8K-IV LBS
Ϫ r-apo(a)
constructs demonstrates apo(a) immunoreactivity, detected by antibody LPA4, as expected ( Fig. 5A ). However, OxPLs detected by antibody EO6 is only present in the 8K-IV WT r-apo(a) but not in the LBS Ϫ r-apo(a) construct. There are no other E06 positive bands throughout the gel, suggesting that there are no other expressed proteins containing signifi cant OxPLs. ELISA shows similar apo(a) levels for both variants, but OxPLs are only present in the WT 8K-IV r-apo(a) and not the LBS Ϫ 8K-IV r-apo(a) construct ( Fig. 5B ) .
Determination of the presence of OxPLs on 8K-IV WT Lp(a) and 8K-IV LBS ؊ Lp(a) transgenic mice
Circulating Lp(a) and apo(a) levels were not statistically different between 8K-IV WT Lp(a) and 8K-IV LBS ؊ Lp(a) mice ( Fig. 6A, C ) . However, OxPL/apoB ( Fig. 6B , P < 0.0001) and OxPL/apo(a) ( Fig. 6D , P < 0.0001) levels were signifi cantly higher in the 8K-IV WT Lp(a) mice compared with the 8K-IV LBS ؊ Lp(a) mice, where levels were essentially nondetectable.
Determination of the presence of OxPLs on r-apo(a) constructs
ELISA of various r-apo(a) constructs was performed to detect the presence of OxPLs using E06. The r-apo(a) constructs were initially captured on microtiter well plates with LPA4 and the amount of apo(a) captured then detected by biotinylated LPA4. For all constructs shown, the levels of r-apo(a) captured in the wells were employing reverse phase LC-MS/MS, using a mixture of PC standards (Avanti Polar Lipids) such as POVPC, PGPC, PAzPC (1-palmitoyl-2-azelaoyl-sn -glycero-3-phosphocholine), ALDO-PC (1-palmitoyl-2-(9 ′ -oxo-nonanoyl)-sn -glycero-3-phosphocholine), and DLPC (1,2-dilinoleoyl-sn -glycero-3-phosphocholine) ( 41, 43, 44 ) . We have applied this methodology to identify noncovalently bound OxPLs on Lp(a) derived from three normal donors with Lp(a) levels ‫ف‬ 90 mg/dl. Lp(a) was isolated by density gradient ultracentrifugation followed by NaCl/ -aminocaproic acid elution on lysine Sepharose. The purifi ed Lp(a) was then extracted with 2:1 chloroform:methanol and the organic phase run on LC-MS/MS. Prominent peaks in the Lp(a) organic phase extract, but not in the aqueous phase, were positively identifi ed as POVPC and PGPC using appropriate identical chromatogram ( Fig. 9B ) . To rule out the possibility that the hydrolysis had destroyed the peptides themselves, we did full scan experiments on samples with and without NH 4 OH treatment and similar patterns of peptides were observed (data not shown). These PC adducts can be hydrolyzed under basic conditions as shown in Fig.  9C , D . These data strongly suggest that the peaks shown in Fig. 9A , B were indeed peptides with covalently modifi ed PC species, not peptides that happen to have fragments with m/z 184 and thus misidentifi ed, otherwise, they would have shown up in Fig. 9C , D .
Determination of OxPLs in lipid phase of Lp(a) using LC-MS/MS following lipid extraction
We had previously demonstrated the ability to separate oxidized and nonoxidized species of varying polarities however, we also found peptides containing PC in the 17K ⌬ Asp 57 construct, which represents a mutation present in the chimpanzee and gorilla, and which were not detected by E06 binding, suggesting either the presence of nonE06-detectable OxPLs or a steric hindrance mediated by the change in the LBS preventing E06 from detecting such OxPLs. Overall, these observations have implications for understanding the role of OxPLs in binding to Lp(a) and mediating human CVD.
Prior studies in transgenic mice have shown that modification of the LBS in KIV 10 results in reduced focal accumulation of apo(a) in mouse aorta following high cholesterol diet ( 35, 48 ) . Modifi cations of this binding pocket are present in all apes and monkeys studied, except the baboon and orangutan, and the apo(a)/Lp(a) from these species does not have EO6 immunoreactivity on ELISA. In most baboons, an intact LBS on apo(a) is functionally present that is similar to the human apo(a) that binds lysine. However, baboon Lp(a), as opposed to apo(a), does not bind to lysine or to plasmin-modifi ed fi brinogen ( 49 ) . Interestingly, KV is absent in baboon apo(a) and thus, in baboon Lp(a) the absence of KV appears to prevent access to lysine resides in the KIV 10 LBS due to altered apo(a) confi rmation causing steric hindrance ( 49 ) . Even in humans, signifi cant lysine binding heterogeneity of apo(a) exists among different subjects, and part of this heterogeneity may be mediated by noncovalent associations of Lp(a) with other circulating proteins that may mask the KIV 10 LBS ( 50, 51 ) .
The role of KIV 10 LBS in mediating binding of OxPLs was further documented by lack of E06 immunoreactivity in r-apo(a) constructs that were designed with various changes in the LBS and other K sites, as well by lack of E06 standards ( Fig. 10 ) . POVPC is known to be detected by E06, but PGPC is not ( 38 ) , confi rming that Lp(a) contains lipid phase E06-detectable and E06-nondetectable OxPLs.
DISCUSSION
In this study we demonstrate several novel observations in the relationship between OxPLs and Lp(a): 1 ) Among all the species tested that have circulating Lp(a), only human Lp(a) contains OxPLs detectable by monoclonal antibody E06; 2 ) The PC-OxPLs in human Lp(a) are both covalently bound to apo(a) and also extractable from the lipid phase; 3 ) Lp(a) transgenic mice expressing a modifi ed human Lp(a) with an intact KIV 10 LBS and the presence of KV contained E06-detectable OxPLs, whereas Lp(a) transgenic mice expressing a very similar apo(a) construct, but in which two critical amino acids of the LBS of apo(a) were modifi ed, did not contain E06-detectable OxPLs. These data, along with similar results in selected r-apo(a) constructs, support the hypothesis that the KIV 10 LBS, along with its well-known property of mediating fi brin binding ( 35, 48 ) , infl uences covalent binding of OxPLs to apo(a) ; 4 ) Lp(a) contains both E06-detectable (POVPC) and nonEO6-detectable (PGPC) OxPLs, consistent with its ability to bind a variety of OxPLs; and 5 ) PC-containing OxPLs were shown to be present by LC-MS/MS on the natural human 17K r-apo(a), consistent with the ability of E06 to bind to this construct. The observation that saponifi cation removed the PC signal from the peptides suggests that this PC was indeed part of a covalently linked OxPL. Surprisingly, KV covalently bound OxPLs, but no experimental confi rmation of the data were presented and nonhuman primate apo(a) containing KV was not evaluated. In contrast, our current results show that the presence of KV is not necessary for OxPL binding, as r-apo(a) constructs lacking KV had strong E06 immunoreactivity. Furthermore, chimpanzees (and bonobos) that have KV did not show E06 immunoreactivity in Lp(a) of mice expressing an LBS ؊ apo(a) transgene. In previous studies ( 13 ) , it was suggested by enzymatic digestion of human apo(a) that KV was the site containing contained OxPLs and that rhesus monkey apo(a), which does not contain KV, had no OxPLs, as demonstrated by lack of E06 immunoreactivity. Computer modeling further suggested that Lys 12 and Lys 42 of , which is substituted in all other Ks in human apo(a) ( 4 ), quite markedly alters the conformation of this K that may allow the histidines to bind OxPLs. Further work removing the entire KIV 10 and/or utilizing site-specifi c mutagenesis of likely immunoreactivity, a fi nding that seems to be explained by their KIV 10 Asp 57 → Ala 57 substitution compared with human apo(a). This observation does not appear to be due to lack of circulating OxPLs, as cholesterol-and fat-fed cynomolgus monkeys with total plasma cholesterol ‫ف‬ 700 mg/dl and abundant E06-detectable OxPLs in atherosclerotic lesions also do not have E06-detectable OxPLs on Lp(a), as shown previously ( 34 ), but they do on PLG which has an intact KIV 10 LBS compared with Lp(a) ( 25 ) . In addition, cynomolgus monkeys do carry OxPLs on apoB particles, as previously shown ( 34 ) .
In general, the most likely amino acids binding OxPLs are cysteines, lysines, and histidines. The seven amino acids that defi ne the KIV 10 LBS do not have terminal amines or in the lipid phase of Lp(a). We previously showed that E06 immunoreactivity was present in organic extracts of human Lp(a) ( 16 ) . Now utilizing LC-MS/MS analyses of organic extracts of human Lp(a), we confi rm that specifi c sites will be needed to identify the exact amino acids involved in the covalent binding of OxPLs.
An important fi nding in this study was that OxPLs are not only present covalently on apo(a) but are also present Fig. 8 . Immunoblotting of various r-apo(a) constructs and human PLG with E06 for PC-OxPL and an anti-apo(a) antibody. Individual constructs are explained in detail in Fig. 2 . Arrows indicate where E06 activity is not present. In these immunoblots OxPLs are denoted to refl ect only E06-detectable OxPLs and not all OxPLs. RLU, relative light units. which is not known to have similar LBS substitutions as apo(a), and that the presence of OxPLs on PLG actually mediates more optimal fi brinolysis ( 25 ) . Thus, the presence of OxPLs on PLG would be expected to be protective against atherothrombosis, as opposed to OxPLs on Lp(a) being pro-atherogenic. This suggests that during evolution, human Lp(a), as opposed to Lp(a) on other species, has further evolved from ape and monkey Lp(a) by regaining the ability to both bind lysine through the KV 10 LBS and also to overtly capture E06-detectable OxPLs.
We have previously shown that the PC of OxPLs present on OxPLs of OxLDL, or apoptotic cells or apoptotic blebs and debris represents a "danger associated mole cular pattern" ( 57 ) , which is recognized by a variety of innate "pattern recognition receptors" such as natural antibodies ( 58 ), scavenger receptors, e.g., CD36 ( 39 ) and C-reactive protein ( 59 ) . Each of these pattern recognition receptors can bind and/or scavenge PC containing OxPLs, which are pro-infl ammatory. In support of this, Lp(a) and its associated OxPLs were recently shown to trigger apoptosis in endoplasmic reticulum-stressed macrophages through a mechanism requiring both CD36 and Toll-like receptor 2 ( 40 ) . In a similar manner, ma londialdehyde epitopes, which represent another well-described oxidation-specifi c epitope resulting from lipid peroxidation, are bound by complement factor H, which protects against the oxidative stress that may mediate age-related macular degeneration ( 60 ) . In future studies, demonstration of human "E06"-like antibodies may provide additional insights into the role of OxPLs in humans as danger-associated molecular patterns and the response of the adaptive and innate immune systems in removing them to protect the host ( 57, 61, 62 ) .
It is now well-established that high levels of Lp(a) are a major risk factor for CAD ( 11 ) . Lp(a) has an increased affi nity for the extracellular matrix of the intima compared with LDL, and one can envision that the enhanced content of OxPLs would make Lp(a) even more pro-infl ammatory. It was previously shown that the LBS of human Lp(a) is a key component in mediating the accumulation of Lp(a) in the intima as well, and in mediating enhanced fatty streak formation ( 35, 48 ) . As shown in this study, such LBS intact Lp(a) as found in humans would also be enriched in OxPLs. This would lead to the hypothesis that an Lp(a) with loss of the LBS would also be associated with in an inability to bind OxPLs and this would be less atherogenic. Studies are underway in the LBS ؊ apo(a)/Lp(a) to assess whether they have less atherogenesis than WT apo(a)/Lp(a) mice with similar Lp(a) levels. Future studies will also need to dissociate LBS features of apo(a) along with the lack of E06 immunoreactivity to assess whether the reduced atherogenesis is due to the defective LBS or the failure to contain OxPLs. Limitations of this study include the lack of adequate nonhuman primate plasma to perform comprehensive studies such as isolation of Lp(a), immunoblotting, or LC-MS/MS of lipid extracts to directly assess for the presence of OxPLs. Whether these species carry OxPLs on other proteins cannot be determined at present. However, the r-apo(a) constructs used covered the key differences in apo(a) present in apes OxPLs are present, such as POVPC, which is recognized by EO6, as well as PGPC, which is not recognized by E06 as previously documented ( 38 ) . This demonstrates that there are OxPLs present in Lp(a) that are not recognized by E06 and suggests that the ability of Lp(a) to bind various OxPLs is a generalized property. The relative amounts of OxPLs on apo(a) versus Lp(a) have not been fully established and may vary according to underlying disease states. Indeed, we found previously that the amount of E06-detectable OxPLs in organic extracts of human Lp(a) varied considerably, with ‫ف‬ 30-70% of E06 immunoreactivity in Lp(a) from various subjects being lipid soluble ( 16 ) .
The r-apo(a) constructs contained covalently bound OxPLs. We speculate that the OxPLs on the r-apo(a) constructs are likely derived from OxPLs generated from apoptotic cells in cell culture ( 52 ) . In vivo, OxPLs on Lp(a) may be derived from hepatocytes during Lp(a) assembly, particularly if there is enhanced hepatocyte oxidative stress, such as in nonalcoholic steatohepatitis ( 53 ) , or transferred to Lp(a) in plasma from atherosclerotic plaques, as suggested by prior human studies in patients undergoing percutaneous coronary intervention ( 22, 54 ) . Importantly, however, our studies of OxPLs on apo(a), expressed both in cell culture and found in mouse plasma, show a similar dependence on an intact LBS in KIV 10 , suggesting that the OxPLs acquired by apo(a) in vitro are a relevant model for those acquired by the apo(a) component of Lp(a) in vivo.
A summary of the differences in Ks, attachment to LDL, protease activity, fi brin binding, and OxPL binding in PLG and apo(a) is given in Fig. 11 . The evolution of Lp(a) in apes and monkeys from PLG has occurred concomitantly with losing the lysine binding properties of the KIV 10 LBS. This has occurred through a variety of mechanisms, including loss of KV and/or modifi cations of KIV 10 LBS ( 49, 55, 56 ) . Along with loss of lysine binding, these species also do not have E06 immunoreactivity on Lp(a). Interestingly, we recently showed that humans, apes, monkeys, and lower species such as mice do have OxPLs on circulating PLG, and monkeys compared with humans and may potentially be considered appropriate apo(a) surrogates.
In summary, E06-and nonE06-detectable PC containing OxPLs are present in the lipid phase of Lp(a) and covalently bound to apo(a). E06 immunoreactivity is strongly infl uenced by the KIV 10 LBS and is unique to human Lp(a), which may explain its pro-atherogenic potential. Human clinical trials with potent Lp(a) lowering agents, that also may reduce their OxPL content ( 31, 32 ) , will provide the ultimate evidence of the atherogenicity of Lp(a) ( 63 ). 
